Company intelligence / Profile preview

Nualtis (formerly IntelGenx Corp.)

Montreal, Quebec, Canada

Ownership: Public · ATAI
Development stage: Other

Overview

Nualtis is recognized for rapid oral absorption products, patient-centric drug delivery innovation, and superior formulation technology. Recent clinical focus includes oral thin film Montelukast for neurodegenerative diseases such as Parkinson's and Alzheimer's, supported in partnership with LTS Lohmann for manufacturing scale-up. Most clinical programs remain confidential; marketed products and OTC collaborations exist.

Therapeutic areas: OtherNeurologyPsychiatry
Modalities: Oral thin film (OTF)Drug delivery systemSmall molecule (delivered via OTF)Biologic (potential, via OTF platform)
Industry: Biotech

Partnerships

LTS Lohmann Therapie-Systeme AGOrthoNuGensco PharmaUS ExeltisXiromed

Beyond the preview

Go deeper on Nualtis (formerly IntelGenx Corp.).

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nualtis (formerly IntelGenx Corp.).

Explore the full profile